The US FDA requests that Novavax finish a new clinical trial for the postponed COVID-19 vaccination. The WSJ reports According to persons familiar with the situation, the Wall Street Journal said Friday that federal
Amplitude Surgical SA (Amplitude) and Zydus Lifesciences Limited (Zydus) attest that Amplitude has consulted with Amplitude SAS's works council and provided the required information. As a result, Zydus has agreed to buy 75.4 percent
The Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization to Entod Pharmaceuticals, a multinational research-driven ophthalmic firm, for a novel ocular formulation designed
Prescription drugs that are often made or contain ingredients from China and India are stocked up in American households.
PCI Pharma Services ("PCI") – an award-winning global contract development and manufacturing company (CDMO) specializing in cutting-edge biopharma therapies – is buying a full equity interest in...
One of the biggest landmarks in the scientific advancement of India has been achieved through an innovative partnership between Bengaluru's Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem) of the Biotechnology Research and...
Syngene International has made a report stating that it has earned a total income of Rs.1036.9 for the period ended March 31, 2025. Leading to the company making a net profit of 183.3 crores for the same period. The company's financial year 20...
After reporting a 22.05 percent increase in consolidated net profit to Rs. 21.70 crore in Q4 FY25 over Q4 FY24, and a 21.34 percent increase in operating revenue to Rs. 187.16 crore, Thyrocare Technologies saw a 15 percent spike to Rs. 884.20.
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago from May 30 to June 3, Pfizer will present data from its entire range of potentially ground-breaking cancer medications.
Sun Pharmaceutical Industries and Moebius Medical, based in Israel, announced that two articles highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis, were published in Osteoarthritis and Cartilage
, CDSCO.jpg)
